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PROTECTION AGAINST TRAUMATIC 
BRAIN INJURY 
FIELD OF THE INVENTION 
The present invention relates to a method for reducing 
adverse effects of a neural injury by administering to a 
patient a therapeutically effective amount of cyclosporin A. 
BACKGROUND OF THE INVENTION 
Severe traumatic brain injuries (TBI) initiate a cascade of 
events that lead to a plethora of adverse effects including 
dramatic elevations of intracranial pressure (ICP) and dys 
function of cerebrovascular regulatory mechanisms essential 
for survival. Ischemic brain injury is observed universally in 
those patients Who die folloWing severe TBI. Intracranial 
hypertension (IH) folloWing traumatic brain injury is asso 
ciated With direct effects on cerebral perfusion Which may be 
responsible for secondary ischemia. The contributions of 
both post-traumatic cerebral edema and alteration in cerebral 
blood volume to ICP appear to vary based on the length of 
time after the primary mechanical insult. This combination 
of vasomotor dysfunction and abnormalities in vascular 
permeability is characteristic of acute in?ammation. 
The mortality rate from severe traumatic brain injury 
(TBI) in the United States alone amounts to 9—30 deaths per 
100,000. Those suffering brain injury requiring medical 
treatment number 160—300 per 100,000, With approximately 
20 percent of patients admitted to treatment facilities sustain 
a moderate to severe degree of injury as measured by the 
GlasgoW Coma Score (GCS) of 3—12. Direct costs of brain 
injury, including the costs of treatment and long-term care, 
as Well as indirect costs, including disablement and the loss 
of productivity of brain injury patients and other such costs, 
are staggering. 
One approach to treating severe traumatic brain injuries is 
With hypothermia, as in US. Pat. No. 5,486,204 to Clifton. 
The procedure includes the introduction of speci?ed medi 
cation to reduce the risk of cardiac arrhythmia and a com 
plicated protocol for the treatment Which de?nes time, 
temperature, rate of change of temperature, the timing of the 
introduction of medications, and rigidly controlled reWarm 
ing to reduce the incidence of reWarming shock in recover 
ing patients. 
There eXists a need to provide simpli?ed methodology for 
treating traumatic brain injuries in mammals, including 
humans. The present invention addresses and solves the 
problems attendant upon multistep, complicated processes 
for treating severe traumatic brain injuries. 
DISCLOSURE OF THE INVENTION 
An object of the present invention is a method of treating 
a mammal suffering from traumatic brain injury. 
Additional objects, advantages and other features of the 
invention Will be set forth in the description Which folloWs 
and in part Will become apparent to those having ordinary 
skill in the art upon examination of the folloWing or may be 
learned from the practice of the invention. The objects and 
advantages of the invention may be realiZed and obtained as 
particularly pointed out in the appended claims. 
According to the present invention, the foregoing and 
other objects are achieved in part by a method of treating a 
mammal, including humans, suffering from traumatic brain 
injury, Which method comprises administering a therapeu 
tically effective amount of cyclosporin A. 
Another aspect of the present invention is a pharmaceu 
tical composition for treatment of severe traumatic brain 
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2 
injuries, the composition comprising an amount of 
cyclosporin A effective for reducing adverse effects of 
traumatic brain injury and pharmaceutically acceptable car 
rier. 
Additional objects and advantages of the present inven 
tion Will become readily apparent to those skilled in this art 
from the folloWing detailed description, Wherein embodi 
ments of the invention are described simply by Way of 
illustrating of the best mode contemplated in carrying out 
the invention. As Will be realiZed, the invention is capable of 
other and different embodiments, and its several details are 
capable of modi?cations in various obvious respects, all 
Without departing from the invention. Accordingly, the 
draWings and description are to be regarded as illustrative in 
nature and not as restrictive. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 illustrates the effect of CsA administration before 
TBI on cortical lesion volume. 
FIG. 2 illustrates the effect of CsA administration pre- and 
post-injury on cortical lesion volume. 
FIG. 3 illustrates the effect of CsA administration pre- and 
post-injury on cortical lesion volume. 
FIG. 4 illustrates the effect of CsA administration after 
TBI on cortical lesion volume. 
DESCRIPTION OF THE INVENTION 
The present invention provides a method of treating a 
mammal, including humans, suffering from traumatic brain 
injury, Which method comprises administering a therapeu 
tically effective amount of cyclosporin A. 
CyclosporinAis knoWn and has been proposed for use for 
various therapeutic methods. For example, US. Pat. Nos. 
4,117,118 and 5,766,629, Which are incorporated herein in 
their entirety by reference thereto, describe this compound, 
methods for preparing this compound, and methods for 
formulating this compound into pharmaceutical composi 
tions. 
The compounds for use in the present invention can be 
administered as a pharmaceutical composition. The pharma 
ceutical compositions used in the methods of this invention 
for administration to animals and humans comprise an active 
agent in combination With a pharmaceutical carrier or 
eXcipient acceptable for delivery of the compounds to the 
brain. 
The pharmaceutical compositions can be in the form of 
tablets (including loZenges and granules), dragees, capsules, 
pills, ampoules or suppositories comprising a compound of 
the invention. 
“Pharmaceutical composition” means physically discrete 
coherent portions suitable for medical administration. “Phar 
maceutical composition in dosage unit form” means physi 
cally discrete coherent units suitable for medical 
administration, each containing a daily dose or a multiple 
(up to four times) or a sub-multiple (doWn to a fortieth) of 
a daily dose of the active compound of the invention in 
association With a carrier and/or enclosed Within an enve 
lope. Whether the composition contains a daily dose, or for 
eXample, a half, a third or a quarter of a daily dose Will 
depend on Whether the pharmaceutical composition is to be 
administered once or, for eXample, tWice, three times or four 
times a day, respectively. 
Advantageously, the compositions are formulated as dos 
age units, each unit being adapted to supply a ?Xed dose of 
active ingredients. Tablets, coated tablets, capsules, 
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ampoules and suppositories are examples of preferred dos 
age forms according to the invention. It is only necessary 
that the active ingredient constitute an effective amount, i.e., 
such that a suitable effective dosage Will be consistent With 
the dosage form employed in single or multiple unit doses. 
The exact individual dosages, as Well as daily dosages, are 
determined according to standard medical principles under 
the direction of a physician or veterinarian. 
The active agents can also be administered as 
suspensions, solutions and emulsions of the active com 
pound in aqueous or non-aqueous diluents, syrups, granu 
lates or poWders. Diluents that can be used in pharmaceu 
tical compositions (e.g., granulates) containing the active 
compound adapted to be formed into tablets, dragees, cap 
sules and pills include the folloWing: (a) ?llers and 
extenders, e.g., starch, sugars, mannitol and silicic acid; (b) 
binding agents, e.g., carboxymethyl cellulose and other 
cellulose derivatives, alginates, gelatine and polyvinyl pyr 
rolidone; (c) moisturiZing agents, e.g., glycerol; (d) disinte 
grating agents, e.g., agar—agar, calcium carbonate and 
sodium bicarbonate; (e) agents for retarding dissolution, 
e.g., paraf?n; resorption accelerators, e.g., quaternary 
ammonium compounds; (g) surface active agents, e.g., cetyl 
alcohol, glycerol monostearate; (h) adsorptive carriers, e.g., 
kaolin and bentonite; lubricants, e.g., talc, calcium and 
magnesium stearate and solid polyethylene glycols. 
The tablets, dragees, capsules and pills comprising the 
active agent can have the customary coatings, envelopes and 
protective matrices, Which may contain opaci?ers. They can 
be so constituted that they release the active ingredient only 
or preferably in a particular part of the intestinal tract, 
possibly over a period of time. The coatings, envelopes and 
protective matrices may be made, for example, from poly 
meric substances or Waxes. 
The active ingredient can also be made up in microen 
capsulated form together, With one or several of the above 
mentioned diluents. 
The diluents to be used in pharmaceutical compositions 
adapted to be formed into suppositories can, for example, be 
the usual Water-soluble diluents, such as polyethylene gly 
cols and fats (e.g., cocoa oil and high esters, (e.g., C14 
alcohol With C16-fatty acid]) or mixtures of these diluents. 
The pharmaceutical compositions Which are solutions and 
emulsions can, for example, contain the customary diluents 
(With, of course, the above-mentioned exclusion of solvents 
having a molecular Weight beloW 200, in the presence of a 
surface-active agent), such as diluents, dissolving agents and 
emulsi?ers. Speci?c non-limiting examples of such diluents 
are Water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, 
ethyl acetate, benZyl alcohol, benZyl benZoate, propylene 
glycol, 1,3-butylene glycol, dimethylformamide, oils (for 
example, ground nut oil, glycerol, tetrahydrofurfuryl 
alcohol, polyethylene glycols and fatty acid esters of sorbitol 
or mixtures thereof. 
For parenteral administration, solutions and suspensions 
should be sterile, e.g., Water or arachis oil contained in 
ampoules and, if appropriate, blood-isotonic. 
The pharmaceutical compositions Which are suspensions 
can contain the usual diluents, such as liquid diluents, e.g., 
Water, ethyl alcohol, propylene glycol, surface active agents 
(e.g., ethoxylated isostearyl alcohols, polyoxyethylene sor 
bitols and sorbitan esters), polycrystalline cellulose, alumi 
num methahydroxide, agar—agar and tragacanth, or mix 
tures thereof. 
The pharmaceutical compositions can also contain bulk 
ing agents and preservatives, as Well as perfumes and 
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?avoring additions (e.g., peppermint oil and eucalyptus oil, 
and sWeetening agents, (e.g., saccharin and aspartame). 
The pharmaceutical compositions Will generally contain 
from about 0.0001 to 90 Wt. %, preferably about 0.01 to 10 
Wt. % of the active ingredient by Weight of the total 
composition. In addition to the active agent, the pharma 
ceutical compositions and medicaments can also contain 
other pharmaceutically active compounds. 
Any diluent in the pharmaceutical compositions of the 
present invention may be any of those mentioned above in 
relation to the pharmaceutical compositions. Such compo 
sitions may include solvents of molecular Weight less than 
200 as the sole diluent. 
The active compound is administered perorally, parenter 
ally (for example, intramuscularly, intraperitoneally, 
subcutaneously, transdermally or intravenously), rectally or 
locally, preferably orally or parenterally, especially 
perlingually, or intravenously. 
The dosage rate, e.g., about 0.0001 to about 200 mg/kg of 
body Weight, such as from about 10 mg/kg to about 150 
mg/kg, preferably from about 20 mg/kg to about 40 mg/kg, 
Will be a function of the nature and body Weight of the 
human or animal subject to be treated, the individual reac 
tion of this subject to the treatment, type of formulation in 
Which the active ingredient is administered, the mode in 
Which the administration is carried out and the point in the 
progress of the disease or interval at Which it is to be 
administered. Thus, it may in some case suffice to use less 
than a minimum dosage rate, While other cases an upper 
limit must be exceeded to achieve the desired results. Where 
larger amounts are administered, it may be advisable to 
divide these into several individual administrations over the 
course of the day. 
It is presently preferred to administer cyclosporin A 
parenterally, such as intravenously, in a bolus, so as to obtain 
the most rapid delivery of the active agent to the brain. A 
suitable dosage for obtaining attenuation of the effects of 
traumatic brain injury is from about 1 to about 1000 mg/kg 
body Weight, such as from about 10 to about 100 mg/kg 
body Weight, although the optimum dosage of cyclosporin A 
Will be determined by the physician taking into account the 
age, Weight and general health of the subject. In other 
embodiments of the present invention, the cyclosporin A 
may be administered directly to the brain, e.g. 
intraventricularly, intracerebrally or intracisternally. The 
dosage may be administered in one or more treatments 
folloWing traumatic brain injury such as by Way of a single 
or multiple doses or from sustained release compositions 
over a period of time, such as immediately after the T131 to 
about 1 or more day after the TBI. Preferably, the initial 
dosage is administered less than about 6 hours after TBI, 
such as from about 15 minutes to about 1 hour after injury. 
HoWever, one or more doses may be administered after 6 
hours such as from about 6 hours to about 24—48 hours after 
injury. 
Cyclosporin A may also be administered in association 
With other therapeutic agents including, for example, anti 
biotics or antiviral agents. 
The folloWing non-limiting examples are given by Way of 
illustration only. 
EXAMPLE 1 
Pretreatment With Cyclosporin A (CsA) in C57B16 Mice 
Adult C57B16 mice Were pretreated With a single sys 
temic injection of one of three different doses of CsA (high 
(150 mg/kg) medium (40 mg/kg) loW (20 mg/kg)) 5 min 
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prior to a moderate cortical contusion. Animals also received 
an additional single systemic injection 24 hr after injury 
(n=8/group). Control animals received vehicle alone. Ani 
mals Were killed 7 days post-injury and the brains assessed 
for changes in lesion volume siZe utilizing image analysis 
and stereology. The lesion volume Was signi?cantly reduced 
in all animals injected With CsA as compared to vehicle 
controls. An AN OVA demonstrated a signi?cant dose effect 
such that the greatest protection Was afforded by animals 
receiving the loWest dose. The animals treated With 20 
mg/kg CsA demonstrated a 45% reduction in lesion volume. 
EXAMPLE 2 
Pre- vs Post-treatment With Cyclosporin A in ICR Mice 
Adult ICR mice Were either pre-treated systemically With 
medium (40 mg/kg) or loW (20 mg/kg) doses of CsA 5 min 
prior to TBI or With a loW dose (20 mg/kg) 15 min after TBI. 
These animals subsequently received an additional injection 
24 h later. Control animals received vehicle 5 min prior and 
24 h after TBI. Seven days after injury the animals Were 
killed and the brains assessed for possible changes in lesion 
volume siZe. All animals receiving CsA shoWed signi?cant 
amelioration of lesion volume and animals treated after the 
injury Were equivalent to pre-treated loW dose animals. In 
addition, the effect Was observed in an additional strain of 
mice. The results are shoWn in FIG. 2. 
EXAMPLE 3 
Pre- vs Post-treatment With CsA in Rats 
Adult SD rats Were either pre-treated systemically With 
medium (40 mg/kg) or loW (20 mg/kg) doses of CsA 5 min 
prior to TBI or With a loW dose (20 mg/kg) 15 min after TBI. 
These animals subsequently received an additional injection 
24 h later. Control animals received vehicle 5 min prior and 
24 h after TBI. Seven days after injury the animals Were 
killed and the brains assessed for possible changes in lesion 
volume siZe. Identical to that found in the mice, all animals 
treated With CsA shoWed signi?cant reductions in the lesion 
volume siZe. Post-injury administration of CsA resulted in 
signi?cant reductions (40%) in lesion volume. The results 
are shoWn in FIG. 3. 
EXAMPLE 4 
Time Course of Initiation of CsA Treatment FolloWing TBI 
We administered CsA at a concentration of 20 mg/kg to 
animals (n=3 adult rats/group) folloWing a moderate level of 
TBI. The CsA therapy (single systemic injection) Was ini 
tiated at different time intervals folloWing the injury (15 m, 
1 h, 6 h, 24 h). Animals Were administered a second injection 
24 h after the ?rst injection. All animals survived for 7 days 
folloWing injury. Brains Were assessed for changes in lesion 
volume siZe utiliZing image analysis and stereological tech 
niques. 
The results, as shoWn in FIG. 4, indicate that the WindoW 
for therapeutic intervention in this model is at least 1 h and 
may even be as long as 24 h. The lack of protection at 6 h 
may relate directly to changes in the blood-brain barrier 
because in this rodent model of TBI, the BBB is opened 
immediately folloWing the injury and then closes rapidly 
(3—6 h post TBI) and reopens around by 24 h. 
DETAILED DESCRIPTION OF THE DRAWINGS 
FIG. 1. 
Cortical lesion volume Was signi?cantly reduced in 
C57B16 mice treated prior to injury With high (150 mg/kg), 
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medium (40 mg/kg), or loW (20 mg/kg) With CsA systemi 
cally. 7 days folloWing TBI mice Were killed and stereo 
logical methods used to determine lesion volume siZe. 
Values are group means (n=8/group):SE *p<0.01 vs 
vehicle *p<0.01 vs medium and high. 
FIG. 2. 
Cortical lesion volume Was signi?cantly reduced in ICR 
mice treated either pre- (medium 40 mg/kg; loW 20 mg/kg) 
or post (20 mg/kg) With CsA systemically. 7 days folloWing 
TBI mice Were killed and stereological methods used to 
determine lesion volume siZe. Values are group means 
(n=8/group):SE *p<0.01 vs vehicle *p<0.01 vs pre 
medium. 
FIG. 3. 
Cortical lesion volume Was signi?cantly reduced in SD 
rats treated either pre- (medium 40 mg/kg/ loW 20 mg/kg) or 
post (20 mg/kg) With CsA systemically. 7 days folloWing 
TBI rats Were killed and stereological methods used to 
determine lesion volume siZe. Values are group means 
(n=10/group):SE *p<0.01 vs vehicle *p<0.01 vs pre 
medium. 
FIG. 4. 
Early initiation of therapy resulted in a signi?cant reduc 
tion in cortical lesion volume. This same level of protection 
of cortical tissue Was also observed With the 1 h delay. If 
treatment Was delayed for 6 h there Was little or no sparing. 
hoWever, a delay of 24 h again shoWed some protection. 
Bars=group meanszSEM (n=3/group). 
In the previous descriptions, numerous speci?c details are 
set forth, such as speci?c materials, structures, chemicals, 
processes, etc., in order to provide a better understanding of 
the present invention. HoWever, the present invention can be 
practiced Without resorting to the details speci?cally set 
forth. In other instances, Well-knoWn processing structures 
have not been described in detail in order not to unneces 
sarily obscure the present invention. 
Only the preferred embodiment of the invention and but 
a feW eXamples of its versatility are shoWn and described in 
the present disclosure. It is to be understood that the present 
invention is capable of use in various other combinations 
and environments and is capable of changes or modi?cations 
Within the scope of the inventive concept as expressed 
herein. 
What is claimed is: 
1. A method for treating a mammal suffering from trau 
matic brain injury caused by an external mechanical force on 
the cerebral corteX, Which method comprises: 
administering a therapeutically effective amount of 
cyclosporin A in a dose from about 1 to about 1000 
mg/kg to a mammal in need thereof Within about 48 
hours after the injury to reduce or ameliorate brain 
tissue damage by reducing lesion volume siZe by more 
than about 5%. 
2. The method of claim 1, comprising: 
administering the cyclosporin A orally. 
3. The method of claim 1, comprising: 
reducing lesion volume siZe by about 10% to about 45%. 
4. The method of claim 1, Wherein the traumatic injury 
results from a non-penetrating head Wound. 
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5. The method of claim 1, comprising: 
administering the cyclosporin A parenterally. 
6. The method of claim 1, comprising: 
administering the cyclosporin A to a human in at least one 
dose Within about 24 hours after injury. 
7. The method of claim 1, comprising: 
administering the cyclosporin Ato a human in at least tWo 
doses Within about 24 hours after injury. 
8. The method of claim 1, comprising: 
8 
administering the cyclosporin A in a dose from about 10 
mg/kg to about 150 mg/kg. 
9. The method of claim 1, comprising: 
administering the cyclosporin A in a dose from about 20 
mg/kg to about 40 mg/kg. 
10. The method of claim 1, comprising: 
administering the cyclosporin A to a human. 
* * * * * 
